[Broncaspin in the therapy of pediatric diseases of the respiratory tract].
A paediatric suspension of Broncaspin was administered to 32 children aged 2-12 yr hospitalised for acute respiratory infection of the respiratory apparatus or hyperpirexia with no evident location. The drug was given as the sole treatment in 9 cases, whereas combination with antibacterial drugs proved indispensable in the other 23 cases. The satisfactory results obtained, together with its excellent tolerability, show that the new preparation is active, and is capable of rapidly eliminating the symptoms, so that the general clinical picture is both evidently and persistently improved.
D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000188:drug therapy; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy; D010998:Pleurisy / Q000188:drug therapy; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D001241:Aspirin; C023557:guacetisal
Il Broncaspin nella terapia delle malattie pediatriche dell'apparato respiratorio.